Delcath Systems (Nasdaq:DCTH) announced today that it entered into a securities purchase agreement worth $7 million in proceeds. The company entered into an agreement with certain accredited investors for the private placement. The collection of investors includes existing investors, Delcath executives and members of the board of directors. Delcath plans to issue and sell 876,627 […]
Delcath Systems Inc.
Delcath Systems appoints new board chair
Delcath Systems (Nasdaq:DCTH) announced today that its board of directors voted to appoint John R. Sylvester as its new chair. Sylvester joined Delcath as a director in July 2019. He currently serves as CEO of Curium Pharma’s SPECT and international businesses. Previously, Sylvester served as BTG’s chief commercial officer, leading the company’s interventional oncology and […]
Delcath Systems raises $6.2M
Delcath Systems (Nasdaq:DCTH) announced today that it closed its previously announced private placement worth $6.2 million. The interventional oncology company issued and sold nearly 1.45 million shares of its common stock at $2.90 per share. In lieu of common stock, it sold 692,042 pre-funded warrants to purchase common stock. Price per warrant totaled $2.89. The […]
Delcath enters into $5M private placement
Delcath Systems (Nasdaq:DCTH) announced today that it entered into a securities purchase agreement worth approximately $5 million. The New York-based interventional oncology company developing treatments for primary and metastatic cancers of the liver will issue and sell 690,954 shares of common stock at a price per share of $3.98. In lieu of shares of common […]
Delcath Systems ticks up despite missed Q1 projections
Delcath Systems (OTC:DCTH) shares ticked up slightly despite first-quarter results that missed the consensus forecast. The New York-based company posted losses of -$6.7 million, or -$1.04 per share, on sales of $388,000 for the three months ended March 31, 2021, for a -33% bottom-line slide on sales growth of 32%. Delcath’s EPS of -$1.04 came […]
Delcath completes $22.2M offering
Delcath Systems (OTC:DCTH) announced that it completed an underwritten public offering of common stock worth approximately $22.2 million. New York-based Delcath’s offering includes nearly 1.7 million shares of its common stock at a public offering price of $13.25 per share, bringing the gross proceeds before deductions to approximately $22.2 million, according to a news release. The […]
Delcath Systems names operations VP
Delcath Systems recently announced that it appointed Kevin Muir as VP of commercial operations. Prior to joining the company, Muir was the director of sales for the embolic interventional oncology business at BTG, which was recently acquired by Boston Scientific. “We are thrilled that Kevin is joining the Delcath team as VP of commercial operations. […]
Delcath names new CEO
Delcath Systems (OTC:DCTH) announced that it appointed Gerard Michel as its new CEO, effective yesterday, Oct. 1, 2020. Michel assumed the role yesterday and also was appointed as a Class I director on the company’s board of directors, with that role continuing until the expiry of his term at the company’s 2022 annual meeting of stockholders, […]
Delcath Systems announces reverse stock split
A reverse stock split went into effect today for Delcath Systems (OTC:DCTH) — developer of the Chemostat hepatic delivery system for treating cancer. The 1-for-700 reverse stock split is meant to reduce the number of common stock shares and shares reserved for issuance to 1.2 million, from a previous 1.4 billion. The authorized number of shares […]
Delcath Systems raises another $9.5m
Delcath Systems (OTC:DCTH) has closed on a $9.5 million private placement round, bringing the total amount raised since July to $29.5 million. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant for […]
Delcath Systems closes $20m private placement
Delcath Systems (OTC:DCTH) last week said that it closed a $20 million private placement round for the liver cancer treatment it developed. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant another […]
